Original Research
Published on 03 Aug 2022
Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
in Thoracic Oncology
![Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC](https://www.frontiersin.org/files/myhome article library/958043/958043_Thumb_400.jpg)
- 4,094 views
- 3 citations